NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX) Is Down 12.1% After Issuing 2026 INGREZZA Sales Guidance - What's Changed
In the past week, Neurocrine Biosciences reported its fourth-quarter and full-year 2025 results, with revenue rising to US$805.5 million for the quarter and US$2.86 billion for the year, alongside higher net income and earnings per share versus 2024.
The company also issued 2026 guidance calling for INGREZZA net product sales of US$2.70 billion to US$2.80 billion, underlining how this franchise and the newer CRENESSITY brand are shaping Neurocrine’s growth profile and funding a sizable...